Riding the Gene Therapy Rollercoaster Into 2026
It has been a tough, if interesting, year for the gene therapy space, with many ups and downs culminating in some optimism and increased funding and investment as 2025 drew to a close.
A continued financial slump in biotech investment after an all-time high in 2021, combined with financial uncertainty triggered by tariffs and inflation concerns at the beginning of Trump’s second term in January, caused the XBI biotech index, a fund that usually indicates the state of the U.S. biotech industry, t...
A continued financial slump in biotech investment after an all-time high in 2021, combined with financial uncertainty triggered by tariffs and inflation concerns at the beginning of Trump’s second term in January, caused the XBI biotech index, a fund that usually indicates the state of the U.S. biotech industry, t...